Cisplatin plus gemcytabine versus cisplatin plus vinorelbine in patients with stage IV nonsmall cell lung cancer (NSCLC): Results of single center experience

被引：1
|
作者：
Er, O
Ozkan, M
Coskun, S
Dogu, G
Altinbas, M
机构：
[1] Erciyes Univ, Fac Med, MK Dedeman Oncol Hosp, Kayseri, Turkey
[2] Suleyman Demirel Univ, Fac Med, Isparta, Turkey
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80974-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
  • [31] Weekly vinorelbine plus cisplatin versus day 1+8 vinorelbine with cisplatin in advanced non small cell lung cancer: End results of a phase III trial
    Gebbia, V
    Galetta, D
    Caruso, M
    LUNG CANCER, 2005, 49 : S32 - S33
  • [32] Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer
    Ramsey, SD
    Moinpour, CM
    Lovato, LC
    Crowley, JJ
    Grevstad, P
    Presant, CA
    Rivkin, SE
    Kelly, K
    Gandara, DR
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (04) : 291 - 297
  • [33] A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN
    de Castro Carpeno, J.
    Castro Gomez, A.
    Walzer, S.
    VALUE IN HEALTH, 2009, 12 (07) : A273 - A274
  • [34] Cost-effectiveness of Gemcitabine (Gemzar™) plus cisplatin versus etoposide plus cisplatin for advanced non small cell lung cancer (NSCLC) in Spain
    Rosell, R
    Sacristan, JA
    Duthie, T
    Cardenal, F
    Artal, A
    Carrato, A
    Lomas, M
    Barneto, I
    Bameto, I
    Massuti, B
    ANNALS OF ONCOLOGY, 1998, 9 : 92 - 93
  • [35] Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide plus gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale
    Gebbia, V
    Galetta, D
    Caruso, M
    Verderame, F
    Pezzella, G
    Valdesi, M
    Borsellino, N
    Pandolfo, G
    Durini, E
    Rinaldi, M
    Loizzi, M
    Gebbia, N
    Valenza, R
    Tirrito, ML
    Varvara, F
    Colucci, G
    LUNG CANCER, 2003, 39 (02) : 179 - 189
  • [36] A cost effectiveness analysis of bevacizumab plus cisplatin and gemcitabine (BCG) versus cetuximab plus vinorelbine and cisplatin (CVC) in patients with advanced or recurrent non-small cell cancer (NSCLC) in Spain
    Castro Carpeno, Javier D.
    Castro Gomez, Antonio J.
    Walzer, Stefan
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S670 - S670
  • [37] Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Nonsmall Cell Lung Cancer
    Hasturk, Serap
    Hatabay, Nilgun
    Ece, Ferah
    Karatasli, Meltem
    Hanta, Ismail
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (03): : 280 - 285
  • [38] Vinorelbine plus oxaliplatin in unfit patients (pts) with stage IV non-small cell lung cancer (NSCLC)
    Mir, O.
    Alexandre, J.
    Ropert, S.
    Durand, J.
    Martin, I.
    Montheil, V.
    Goldwasser, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC)
    Walzer, S.
    de Castro Carpeno, J.
    Vergnenegre, A. V.
    Chouaid, C.
    Heigener, D. F. H.
    Bischoff, H. G.
    Nicolson, M. C.
    Aultman, R.
    Siebert, U.
    EJC SUPPLEMENTS, 2009, 7 (02): : 555 - 555
  • [40] Comparison of Vinorelbine plus Cisplatin and S-1 plus Cisplatin in Concurrent Chemoradiotherapeutic Regimens for Unresectable Stage III Non-small Cell Lung Cancer
    Shukuya, Takehito
    Takahashi, Toshiaki
    Harada, Hideyuki
    Akamatsu, Hiroaki
    Sakaguchi, Chikara
    Imai, Hisao
    Ono, Akira
    Nakamura, Yukiko
    Tsuya, Asuka
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Takahashi, Kazuhisa
    Yamamoto, Nobuyuki
    ANTICANCER RESEARCH, 2012, 32 (02) : 675 - 680
12345